CloudMD Software & Services Inc., - CEO, Dr Essam Hamza.
CEO, Dr Essam Hamza.
Source: The Vancouver Sun.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • CloudMD (DOC) has expanded its virtual mental health services by purchasing Aspiria
  • Aspiria is a healthcare provider focused on delivering employee and student assistance programs
  •  Aspiria’s current annualized revenue run rate is approximately $3.4 million
  • The latest aquisition will become part of CloudMD’s enterprise health solutions division
  • CloudMD is up 2.25 per cent to C$2.27 per share

CloudMD (DOC) has expanded its virtual mental health services by purchasing Aspiria.

Established in 2003, Aspiria is a healthcare provider focused on delivering employee and student assistance programs.

The Vancouver-based telehealth company signed a binding term sheetto acquire 100 per cent of the company.Aspiria currently serves over 750 organizations and one million people globally. Its current annualized revenue run rateis approximately $3.4 million.

Aspiria Founder and CEO Charles Benayon said becoming part of the CloudMD family means both companies can do more to motivate organizations on their journeys to better health.

“With access to CloudMD’s incredible resources, knowledge and global platform, the transformation of delivering mental health care to organizations in the employer and student markets will be truly limitless,” Benayon said.

Aspiria provides a technology-driven mental health support solution that gives access to clinical services for mental and situational life issues impacting wellbeing.

CloudMD will leverage Aspiria’s technology and digital care solutions combined with traditional in-person counselling to meet the unique needs of students and employees across North America.

Aspiria will become part of CloudMD’s enterprise health solutions division. It will also complement CloudMD’s other mental health solutions including Snapclarity and HumanaCare to promote effective and efficient clinical best practices in managing mild, moderate and chronic conditions.

The addition of Aspiria increases CloudMD’s clinical network to approximately 7,500 therapists and mental health professionals in North America.

For the purchase of 100 per cent of the outstanding securities of Aspiria, CloudMD agreed to pay shareholders an aggregate consideration of $3 million payable as follows: $1.2 million in cash, subject to a working capital adjustment; $1.05 million in common shares of the company; and a performance-based earnout of $0.75 million, which is payable in common shares of the company after a period of one year.

CloudMD is up 2.25 per cent to C$2.27 per share at 12:09pm EST.

More From The Market Herald
Rakovina Therapeutics Inc. (TSXV:RKV) - Executive Chairman- Jeffrey Bacha.

" Rakovina (TSXV:RKV) advancing trial programs for cancer treatment

Rakovina Therapeutics (RKV) is advancing its programs for malignant tumour treatment therapies.
MedMira Inc. - CEO, Hermes Chan

" MedMira (TSXV:MIR) gets CE mark during new device regulations

MedMira Inc. (MIR) has received the CE mark for three of seven products submitted this year.
The Market Herald Video

" Empower Clinics (CSE:CBDT) accredited for Covid-19 mobile testing in B.C.

Empower Clinics (CBDT) has received accreditation for its COVID-19 mobile testing solutions.

" Revive (CSE:RVV) gets FDA OK for Bucillamine trials to treat COVID-19

Revive Therapeutics (RVV), a cannabis and psychedelic healthcare company has received feedback from the U.S. FDA to help advance Bucillamine.